The two organizations first announced the acquisition in July.
Evolent officials initially predicted the deal would cost approximately $145 million. Officials said the final number is based on the closing price of Evolent’s stock, which traded at more than $24 per share on Tuesday when the deal was finalized.
According to the agreement, Evolent will acquire the majority of Valence, apart from its contracts serving state insurance co-ops. Those shares will be transferred to a separate entity owned by Valence shareholders, according to the article.
Evolent officials expect Valence to generate revenues between $80 and $85 million in 2016, according to the article.
More articles on transactions and valuations:
Philadelphia Eagles’ Carson Wentz partners with Sanford Health
Louisiana reaches deal with BRF hospital operator
OCH Hospital acquires Carthage Children’s Clinic
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.